Cellectar Biosciences Presents Compelling Efficacy Data from Phase 2b CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Relapsed/Refractory to BTK Inhibitor Therapy at the International Works
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
| Cellectar Biosciences, Inc. (NASDAQ: CLRB) | Delayed: 1.22 +0.01 (0.83%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.21 | 52 Week High | $6.03 | |||
| Open | $1.23 | 52 Week Low | $0.41 | |||
| Day High | $1.26 | P/E | N/A | |||
| Day Low | $1.18 | EPS | $0.00 | |||
| Volume | 66,544 | |||||
